Cancer News and Research

Latest Cancer News and Research

Potential breakthrough in treating late-stage ovarian cancer

A potential breakthrough in treating late-stage ovarian cancer has come from University of Guelph researchers who have discovered a peptide that shrinks advanced tumours and improves survival rates for this deadly but often undetected disease.

17 Nov 2011

New 2-DG-ABT combination cancer therapy triggers apoptosis

Researchers at the University of California, San Diego School of Medicine and Kyushu University Medical School say a novel combination of a specific sugar molecule with a pair of cell-killing drugs prompts a wide variety of cancer cell types to kill themselves, a process called apoptosis or programmed cell death.

17 Nov 2011

Researchers identify potential marker for leukemic relapse

The development of simple tests to predict a leukemic relapse in young patients is a step closer thanks to researchers from the Sainte-Justine University Hospital Research Center and the University of Montreal. Approximately 20 percent of young leukemia patients who are treated with stem cells derived from umbilical cord blood will experience leukemic relapse.

17 Nov 2011

SHARPIN protein regulates human cell activity

The research teams headed by Prof. Johanna Ivaska (University of Turku and VTT Technical Research Centre of Finland) and Prof. Marko Salmi (University of Turku and the National Institute for Health and Welfare) have discovered that the SHARPIN protein regulates human cell activity.

17 Nov 2011

Breakthrough in loading gold nanorods into cells could lead to new cancer treatment

Rice University chemists have found a way to load more than 2 million tiny gold particles called nanorods into a single cancer cell. The breakthrough could speed development of cancer treatments that would use nanorods like tiny heating elements to cook tumors from the inside.

17 Nov 2011

Bionovo initiates Menerba Phase 3 trial in menopausal hot flashes

Bionovo, Inc., a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, today announced that the first patient has now been randomized and will begin dosing in the Phase 3 pivotal clinical trial evaluating the safety and efficacy of two doses of Menerba (MF101) among a cohort of postmenopausal women for the treatment of menopausal hot flashes.

17 Nov 2011

Incyte receives FDA approval for Jakafi to treat intermediate or high-risk MF

Incyte Corporation today announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Jakafi (ruxolitinib) for the treatment of patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF and post-essential thrombocythemia MF.

17 Nov 2011

Additional results from BioSante's LibiGel pK study on HSDD

BioSante Pharmaceuticals, Inc., today announced additional results from its principal LibiGel (testosterone gel) pharmacokinetic (pK) study. Top line data from this study were announced on September 12, 2011.

16 Nov 2011

Mirna reports new preclinical data of miRNA-based therapeutic candidate for hepatocellular carcinoma

Mirna Therapeutics, Inc., a biotechnology company pioneering microRNA replacement therapy for cancer, announced the presentation today of new preclinical data on the development of a miRNA-based therapeutic candidate for primary liver cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in San Francisco, CA.

16 Nov 2011

Geron bows out of stem cell research

Geron Corp. is removing itself from the field it pioneered – stem cell research. Late Monday, the company said it would halt its study of a stem cell-based treatment for spinal cord injury, the first embryonic stem cell trial approved in the U.S.

16 Nov 2011

Human pluripotent stem cells rely heavily on glycolysis to drive their metabolic activities

Human pluripotent stem cells, which can develop into any cell type in the body, rely heavily on glycolysis, or sugar fermentation, to drive their metabolic activities.

16 Nov 2011

Aileron, Roche to expand Stapled Peptide drug collaboration

Aileron Therapeutics announced today that Roche will initiate a new program to expand its collaboration with Aileron to discover, develop and commercialize Stapled Peptide drugs.

16 Nov 2011

Molecular level insights into connection between cancer and diabetes

Developing type 2 diabetes is a lengthy process. An early sign that it has begun is high levels of insulin in the blood. As long as the insulin-producing beta cells are able to compensate for the increased demand, for example when the individual is overweight, the blood sugar levels remain normal. It is not until the capacity for insulin secretion falls below the level needed that type 2 diabetes becomes a fact. The latter stage generally goes quickly, as the stressed beta cells work themselves to death.

16 Nov 2011

Scarring prevents precipitous decline in heart function after cardiac injury

After a heart attack, the portions of the heart damaged by a lack of oxygen become scar tissue. Researchers have long sought ways to avoid this scarring, which can harden the walls of the heart, lessen its ability to pump blood throughout the body and eventually lead to heart failure. But new research from the University of North Carolina at Chapel Hill School of Medicine shows that interrupting this process can weaken heart function even further.

16 Nov 2011

Community-based cancer screening may increase awareness of smoking, reduce at-risk behaviors

Large, population specific community-based screening may increase awareness of the dangers of smoking and reduce at-risk behaviors, according to a new study in the November 2011 issue of Otolaryngology-Head and Neck Surgery.

16 Nov 2011

Researchers produce normal sperm from mouse cells

A Ben-Gurion University of the Negev researcher has achieved a significant breakthrough in male fertility, producing normal sperm from mouse cells.

16 Nov 2011

ZIOPHARM announces new preclinical data from two darinaparsin studies on solid tumors

ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, announced today new preclinical data from two separate studies of darinaparsin, a novel organic arsenic, in various solid tumor models at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place November 12-16 in San Francisco.

16 Nov 2011

Amgen receives EC approval to extend therapeutic indications for Vectibix

Amgen today announced that the European Commission (EC) has approved a variation to the marketing authorization for Vectibix (panitumumab) to include indications for the treatment of patients with wild-type KRAS metastatic colorectal cancer (mCRC) in first-line in combination with FOLFOX and in second-line in combination with FOLFIRI in patients who have received first-line fluoropyrimidine-based chemotherapy.

16 Nov 2011

Advaxis licenses ISG15 tumor antigen from University of Pennsylvania

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has exclusively licensed the use of antigen ISG15 in Advaxis' Lm-LLO based immunotherapies from the University of Pennsylvania.

16 Nov 2011

Researchers to begin drug development projects for rare and neglected diseases

Researchers will begin drug development projects for rare and neglected diseases that include potential treatments for a musculoskeletal disorder, a cognitive dysfunction disorder, a virus that affects the central nervous system of newborns, a parasitic worm infection, a form of muscular dystrophy and a rare lung disease.

16 Nov 2011